Breaking News, Collaborations & Alliances

Goodwin Biotechnology and Aspyrian Therapeutics Form Pact

Collaboration will focus on GMP manufacturing and IND submission for a novel antibody drug conjugate platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Goodwin Biotechnology, Inc., a biological contract development and manufacturing organization (CDMO) that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing mammalian cell culture expression systems and bioconjugation technologies, has partnered with Aspyrian Therapeutics to complete process development, scale-up, and cGMP manufacturing of their novel antibody drug conjugate (ADC). Based on achieving this critical milestone, Aspyrian Therapeutics recen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters